PCSK9 Phase 1 duration: 18 months

Anthropic Files $965B IPO, Trump Signs AI Executive Order, … · Jun 6, 2026

The LDL reduction from the VRRV-102 PCSK9 gene-editing therapy was sustained for up to 18 months in the Phase 1 trial — from a single infusion.